Cytosorbents CORP 8-K Filing
Ticker: CTSO · Form: 8-K · Filed: Nov 13, 2025 · CIK: 1175151
| Field | Detail |
|---|---|
| Company | Cytosorbents CORP (CTSO) |
| Form Type | 8-K |
| Filed Date | Nov 13, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Cytosorbents CORP (ticker: CTSO) to the SEC on Nov 13, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (nge on which registered Common Stock, $0.001 par value NASDAQ Check the appropri).
How long is this filing?
Cytosorbents CORP's 8-K filing is 2 pages with approximately 499 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 499 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-11-13 16:34:39
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value NASDAQ Check the appropri
Filing Documents
- a8k.htm (8-K) — 24KB
- exhbit99-1.htm (EX-99) — 594KB
- image00002.jpg (GRAPHIC) — 9KB
- 0000929638-25-004243.txt ( ) — 794KB
- ctso-20251113.xsd (EX-101.SCH) — 4KB
- ctso-20251113_lab.xml (EX-101.LAB) — 21KB
- ctso-20251113_pre.xml (EX-101.PRE) — 16KB
- a8k_htm.xml (XML) — 4KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On November 13, 2025, CytoSorbents Corporation issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.*
01
Item 9.01 Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release of the Company, dated November 13, 2025 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) * The information in Item 2.02 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 13, 2025 CYTOSORBENTS CORPORATION By: /s/ Dr. Phillip P. Chan Name: Dr. Phillip P. Chan Title: Chief Executive Officer